Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation.

and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. He is participating in ongoing clinical trials of tolvaptan for the treatment of autosomal dominant polycystic kidney disease sponsored by Otsuka Pharmaceutical Development and Commercialization Inc, and is a consultant to Forest Research Institute Inc and Primrose Therapeutics Inc. A.M. has received honoraria from CSL Behring. B.C. is an inventor of abciximab (Centocor) and, in accord with Federal law and the policies of the Research Foundation of the State University of New York, receives royalties based on the sales of abciximab; is an inventor of the VerifyNow assays (Accumetrics) and, in accord with Federal law and the policies of the Mount Sinai School of Medicine, receives royalties based on the sales of the VerifyNow assays; is an inventor of small molecule ␣IIb␤3 antagonists (RUC-1 and RUC-2) and Rockefeller University has applied for patents on these molecules. D.G.B. has received grant/research support from Otsuka Pharmaceuticals for treatment of polycystic kidney disease with tolvaptan, a vasopressin V2 receptor antagonist. The remaining authors declare no competing financial interests. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. directly regulates cyst growth in polycystic kidney disease.pressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. We describe a successful salvage treatment with intensive chemo-therapy and stem cell transplantation for a relapse of Hodgkin lymphoma (HL) after single umbilical cord blood transplantation with a reduced intensity-conditioning regimen (RIC). 1,2 The originality of this observation is the source of cells for the second transplantation; the grafted cells were obtained by the mobilization in the blood of stem cells (PBSCs) originating from the cord blood unit (CBU) used for the previous transplantation. A 24-year-old patient was diagnosed with a nodular sclerosis classic HL (stage II Bb according to the Ann Arbor classification) in May 2007. A primary refractory disease was observed after 4 courses of adriamycin, bleomycin, vinblastine, and decarbazine (ABVD); 2 courses of mitoguazone, ifosfamide, vinorelbine, and etoposide plus rituximab (MINER); 2 courses of high-dose cytarabine (Ara-C), cisplatin, and dexamethasone (DHAP); and cervical irradiation (supplemental Table 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article). In August 2008, despite the availability of autolo-gous stem cells …